Gamida Cell Ltd.
Israeli cell therapy company developing stem cell treatments for cancer and blood diseases, now operating as private subsidiary of UK-based Ayrmid Ltd. following 2024 restructuring
Take Action
Apply pressure where it matters. Use these tools and personalise your message with evidence from this page.
- Contact Corporate LeadershipPre-filled letter templates for healthcare industry pressure
- Report New IntelligenceSubmit evidence of contracts, partnerships, or complicity
- Share This ProfileShare on LinkedIn to reach healthcare professionals
- Strategic AnalysisIn-depth analysis and engagement strategy
Before taking action, review our Code of Conduct for professional standards and ethical guidelines.
Help Us Hold Gamida Cell Ltd. Accountable
Your skills and knowledge can strengthen this campaign. Join our volunteer research team or share insider information securely.
Leverage Your Expertise
Do you work in this sector? We need professionals who understand procurement cycles, regulatory compliance, and corporate governance. Don't just boycott - lead!
Decision-Maker Directory
Key individuals with influence over corporate partnerships and procurement decisions. Direct your correspondence to the most relevant role.
Material Risk Framing
Frame your message around business risks. These talking points resonate with corporate stakeholders and institutional investors.
Pharmaceutical products subject to FDA regulation; no documented military applications; healthcare necessity complicates boycott
Now private company following 2024 delisting; owned by Highbridge Capital via UK entity Ayrmid Ltd.; limited investor pressure mechanisms
Low public visibility as B2B biotech; healthcare products create ethical complexity for boycott messaging
Specialised cell therapy with limited alternatives; third-party manufacturing via RoslinCT in Massachusetts
Strategic Analysis
In-depth assessment of the company's position, vulnerabilities, and recommended approaches for effective engagement.
Lower severity, lower vulnerability — watch list, gather intel
Learn about our methodology — companies are categorised based on severity (harm potential) vs strategic vulnerability (campaign leverage).
Why do these scores change?
Unlike static boycott lists, our targeting model is dynamic. This company's position on the matrix is re-evaluated continually as we verify new contracts, divestments, or policy changes. Your reporting directly impacts this score.
Gamida Cell represents a low-priority monitoring target following its 2024 transition from public to private company. Originally headquartered in Jerusalem, the company now operates as a subsidiary of UK-based Ayrmid Ltd. under Highbridge Capital ownership. While Israeli production continues at Kiryat Gat, the company's delisting eliminates most investor pressure mechanisms and reduces its strategic relevance for active boycott campaigns.
Key Leverage Points
- Limited Pressure Mechanisms: Private ownership eliminates shareholder activism and public market pressure
- Healthcare Complexity: Cell therapy products serve critical medical needs, complicating boycott messaging
- Reduced Israeli Operations: Jerusalem R&D centre closed; only Kiryat Gat production remains
- UK Parent Structure: Ayrmid Ltd. ownership creates additional corporate distance from Israeli operations
Strategic Context
Gamida Cell's transition to private ownership fundamentally changes its vulnerability profile. The company entered restructuring in March 2024 after failing to find a strategic partner, with Highbridge Capital converting $75 million in debt to equity and investing $30 million in new capital. The 2024 restructuring included closing the Jerusalem R&D centre and laying off 25% of workforce. Production continues at the Kiryat Gat facility in Israel, maintaining economic contribution to the Israeli economy, though at reduced scale.
The December 2025 FDA approval for Omisirge in severe aplastic anaemia demonstrates continued commercial activity, with manufacturing partnership with RoslinCT in Massachusetts beginning commercial production in 2027. This US-based manufacturing may further reduce Israeli operational footprint over time.
Engagement Strategy
Given private ownership and healthcare complexity, this target warrants monitoring rather than active campaign. Document ongoing Israeli operations at Kiryat Gat for inclusion in broader Israeli biotech sector analysis. Engage healthcare procurement professionals on supplier diversification principles when discussing the broader Israeli pharmaceutical sector. Focus active campaign resources on higher-impact targets with greater vulnerability and public pressure mechanisms. Update profile if company returns to public markets or significant Israeli operational expansion occurs.
Evidence & Sources
Verified sources including NGO reports, regulatory filings, and primary documents. Use these to substantiate your correspondence.
Second FDA approval for Omisirge, now indicated for severe aplastic anaemia in addition to blood cancer
Open sourceGamida Cell announces new executive team led by Dr. Joe Wiley as CEO following completion of restructuring
Open sourceFINRA confirms Gamida Cell begins OTC trading following NASDAQ delisting
Open sourceIsraeli business news reports on NASDAQ delisting and Highbridge taking full ownership
Open sourceCompany announces restructuring with Highbridge Capital, NASDAQ delisting, and Jerusalem office closure
Open sourceUpdates & Milestones
- Second FDA Approval
Omisirge approved for severe aplastic anaemia, first cell therapy for this indication
- Restructuring Completed
Gamida Cell becomes wholly owned subsidiary of Ayrmid Limited (UK); new executive team appointed
- NASDAQ Delisting
Shares delisted from NASDAQ; brief OTC trading before going fully private
- Jerusalem Office Closed
Jerusalem R&D centre wound down; 25% workforce laid off; operations consolidated to Kiryat Gat production facility
- Restructuring Announced
Company enters restructuring with Highbridge Capital; $75M debt converted to equity, $30M new capital invested
- First FDA Approval
Omisirge (omidubicel-onlv) receives FDA approval for blood cancer patients undergoing stem cell transplant
- Company Founded
Gamida Cell established in Jerusalem, Israel as cell therapy developer